PepGen Inc PEPG
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-05-06 |
| Shares Out. | 69,170,000 |
| Website | pepgen.com ↗ |
| Phone | 17034568000 |
| Employees | 59 |
| Net Income | -$17.8M |
| Free Cash Flow | -$77.3M |
| Total Assets | $156.3M |
| Total Liabilities | $22.3M |
| Equity | $134.0M |
About PepGen Inc
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
PepGen Inc is a publicly traded company under the ticker symbol PEPG on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)